X

Drug Profile

CNF 2024

Alternative Names: BIIB-021; CNF2024

Latest Information Update: 02 Oct 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biogen Idec
Class Antineoplastics; Purines; Small molecules
Mechanism of Action HSP90 heat-shock protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

Highest Development Phases

Discontinued Breast cancer; Gastrointestinal stromal tumours; Solid tumours

Most Recent Events

01 Apr 2011 Biogen Idec completes a phase I trial in Breast cancer (combination therapy) in USA (NCT00412412)
04 Feb 2011 CNF 2024 is available for licensing as of 04 Feb 2011. www.biogenidec.com
06 Jan 2011 Biogen Idec completes a phase I trial (NCT00618735) in Solid tumours in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com